Insulin Pump Market Report by Types (Tethered Pumps, Patch Pumps, Consumables), Diseases (Type 1 Diabetes, Type 2 Diabetes), Accessories (Action Figures Insulin Reservoirs, Infusion Sets, Infusion Set Insertion Devices), End-user (Action Figures Hospital and Clinics, Home Care, Others) Countries and Company Analysis 2024-2032

Global Insulin Pump Market Size

Insulin Pump Market value is expected to be around US$ 11.12 Billion by 2032 compared to US$ 4.63 Billion by 2023. The CAGR for the Insulin Pump Industry from 2024 to 2032 is 10.23%.

The technology for insulin pumps is rapidly evolving. An insulin pump is a wearable medical device that supplies a continuous flow of rapid-acting insulin underneath your skin. Most pumps are small, computerized devices that are roughly the size of a juice box or a deck of cards. Insulin pumps are an alternative to multiple daily injection (MDI) insulin therapy (syringe or pen injections) for people with diabetes who require insulin to manage the condition. 

Insulin Pump Market Survey

• A survey by SVB Leerink found that insulin pump adoption increased by 21% in 2021.
• According to a PMC study, about 100% of patients found the insulin pump therapy better than their previous treatment with insulin pens or syringes. In 81.1% of the patients, the insulin pump decreased the frequency of hypoglycemic episodes.
• According to the NCBI, as of 2022, about 350,000 people in the United States use insulin pumps, with 90% of them having type 1 diabetes and 10% having type 2 diabetes.
• According to the 2019-20 National Diabetes Audit, about 15% of people with type 1 diabetes in the UK use an insulin pump, which is around 60,000 people.
• According to RKI, in 2021, 8,699 people in Germany were newly diagnosed with type 1 diabetes, including 3,790 women and 4,908 men. The number of people using insulin pumps has increased from 56 to 75 per clinical unit, which is a 34% increase.
• In 2021, 66% of adults in Denmark used insulin pumps, up from 59% in 2017.
• In 2023, 9,353 patients in the Netherlands use insulin pumps, which is about 4.8% of the population. 3,756 patients use both insulin pumps and continuous glucose monitoring, which is about 1.9% of the population.
• As of October 2023, nearly 50,000 people in China with diabetes use insulin pumps long-term, and more than 3,000 hospitals use insulin pump therapy. However, a survey from 2022 found that only 15.21% of patients with type 1 diabetes use insulin pumps, and this only includes children under 14 who have recently been diagnosed, as per NCBI.

India Insulin Pump Market

According to a 2023 government study, 11% of India's population has diabetes, which is 101 million people. India Insulin Pumps Market is highly competitive, with a number of international and domestic players competing for market. Major growth drivers for India insulin pumps market include increasing prevalence of diabetes in the country and increasing awareness of the benefits of insulin pump therapy among both patients and healthcare professionals. Insulin pumps offer a number of advantages over traditional insulin injection therapy, including more precise dosing and the ability to continuously monitor blood glucose levels. As awareness of these benefits grows, more patients are expected to adopt insulin pump therapy. According to studies, the incidence of Type 1 diabetes is rising at a rate of approximately 3-5% per year. While Type 1 diabetes is largely hereditary, it can also be triggered by an autoimmune response to viruses or the environment. Insulin pumps are also frequently utilized by people diagnosed with Type 2 diabetes in India.

• In March 2022, Medtronic India launched the MiniMed 780G, a closed loop insulin pump system for type 1 diabetes.
• In 2023, Pfizer acquired Seagen for around US$ 43 Billion, the biggest biopharma M&A deal.

Insulin Pump Market Company Analysis

Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche, Insulet Corp., Ypsomed Holding AG, and Microtech Medical are critical businesses in the global insulin pump market.

Insulin Pump Market Company News

• In January 2024 - Abbott and Tandem Diabetes Care, Inc. revealed that the t: slim X2 insulin pump featuring Control-IQ technology is the inaugural automated insulin delivery (AID) system to incorporate the recently launched FreeStyle Libre 2 Plus sensor, Abbott's latest continuous glucose monitoring (CGM) innovation.
• In January 2023 - Tandem Diabetes Care finalized its acquisition of AMF Medical, the maker of the Sigi patch pump for insulin delivery. Despite Tandem's plans to acquire AMF Medical, the Switzerland-based company does not offer Sigi commercially. Notably, the Sigi system received FDA breakthrough device designation over a year ago.
• In February 2023 - Insulet Corporation, known for its Omnipod® brand of products, acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies. The acquisition, valued at US$ 25 Million, includes specific Bigfoot patents associated with pumps suitable for AID therapy.
• In November 2023 - ViCentra B.V., the company behind Kaleido, unveiled a Hybrid closed-loop system for automated insulin delivery in partnership with Diabeloop DBLG1 control software and Dexcom G6 CGM sensor. This advanced system improves users’ Time in Range glucose values by 16.7%.

Types – Market breakup in 3 viewpoints:

1.    Tethered Pumps
2.    Patch Pumps
3.    Consumables

Diseases – Market breakup in 2 viewpoints:

1.    Type 1 Diabetes
2.    Type 2 Diabetes

Accessories – Market breakup in 3 viewpoints:

1.    Action Figures Insulin Reservoirs
2.    Infusion Sets
3.    Infusion Set Insertion Devices

End-user – Market breakup in 3 viewpoints:

1.    Action Figures Hospital and Clinics
2.    Home Care
3.    Others

Countries – Market breakup of 25 Countries:

1.    North America

1.1    United States 
1.2    Canada

2. Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands 
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    United Arab Emirates
5.3    South Africa

All the Key players have been covered from 3 Viewpoints:

•    Overview
•    Recent Development
•    Revenue Analysis

Company Analysis:

1.    Medtronic
2.    Insulet Corporation
3.    Tandem Diabetes Care
4.    Roche
5.    Insulet Corp.
6.    Ypsomed Holding AG
7.    Microtech Medical

Report Details: